PE20231183A1 - PHARMACEUTICAL COMPOSITION WITH ELECTROSTATIC CHARGE AND METHOD OF OBTAINING - Google Patents

PHARMACEUTICAL COMPOSITION WITH ELECTROSTATIC CHARGE AND METHOD OF OBTAINING

Info

Publication number
PE20231183A1
PE20231183A1 PE2023001213A PE2023001213A PE20231183A1 PE 20231183 A1 PE20231183 A1 PE 20231183A1 PE 2023001213 A PE2023001213 A PE 2023001213A PE 2023001213 A PE2023001213 A PE 2023001213A PE 20231183 A1 PE20231183 A1 PE 20231183A1
Authority
PE
Peru
Prior art keywords
agent
pharmaceutical composition
electrostatic charge
obtaining
electrostatic
Prior art date
Application number
PE2023001213A
Other languages
Spanish (es)
Inventor
Palma Miryam Perez
Rangel Gustavo Eduardo Posadas
Rico Jacobo Alejandro Gomez
Original Assignee
Posi Visionary Solutions Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Posi Visionary Solutions Llp filed Critical Posi Visionary Solutions Llp
Publication of PE20231183A1 publication Critical patent/PE20231183A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
    • A62B23/00—Filters for breathing-protection purposes
    • A62B23/06—Nose filters

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • Emergency Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA TOPICA CON CARGA ELECTROSTATICA EN FORMA DE GEL QUE COMPRENDE: A) LA COMBINACION DE AL MENOS UN AGENTE DE CARGA ELECTROSTATICA DE NATURALEZA CATIONICA SELECCIONADA DE ENTRE CLORURO DE BEHENTRIMONIO, CLORURO DE CETRIMONIO Y CLORURO DE BENZALCONIO, O COMBINACIONES DE LOS MISMOS, CON UNA GOMA CATIONICA, EN UN PORCENTAJE DE ENTRE 0.1 % HASTA 15.0 %; B) UN AGENTE DE AJUSTE DE PH; C) UN AGENTE ACIDULANTE TAL COMO ACIDO TARTARICO; Y D) UNA COMPOSICION BASE FORMADA POR UN VEHICULO, UN AGENTE VISCOSANTE Y UNO O MAS HUMECTANTES. TAMBIEN SE REFIERE A UN PROCESO PARA LA MANUFACTURA DE DICHA COMPOSICION TOPICA ELECTROSTATICA.REFERRING TO A TOPICAL PHARMACEUTICAL COMPOSITION WITH AN ELECTROSTATIC CHARGE IN THE FORM OF A GEL WHICH COMPRISES: A) THE COMBINATION OF AT LEAST ONE ELECTROSTATIC CHARGING AGENT OF A CATIONIC NATURE SELECTED FROM BEHENTRIMONIUM CHLORIDE, CETRIMONIUM CHLORIDE AND BENZALKONIUM CHLORIDE, OR COMBINATIONS OF THE THE SAME, WITH A CATIONIC GUM, IN A PERCENTAGE OF BETWEEN 0.1% UP TO 15.0%; B) A PH ADJUSTMENT AGENT; C) AN ACIDULATING AGENT SUCH AS TARTARIC ACID; AND D) A BASE COMPOSITION FORMED BY A VEHICLE, A VISCOSANT AGENT AND ONE OR MORE HUMECTANTS. IT ALSO REFERS TO A PROCESS FOR THE MANUFACTURING OF SAID ELECTROSTATIC TOPICAL COMPOSITION.

PE2023001213A 2020-09-25 2020-09-25 PHARMACEUTICAL COMPOSITION WITH ELECTROSTATIC CHARGE AND METHOD OF OBTAINING PE20231183A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/058972 WO2022064254A1 (en) 2020-09-25 2020-09-25 Pharmaceutical composition with electrostatic charge and use thereof

Publications (1)

Publication Number Publication Date
PE20231183A1 true PE20231183A1 (en) 2023-08-11

Family

ID=80845010

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001213A PE20231183A1 (en) 2020-09-25 2020-09-25 PHARMACEUTICAL COMPOSITION WITH ELECTROSTATIC CHARGE AND METHOD OF OBTAINING

Country Status (6)

Country Link
BR (1) BR112023005563A2 (en)
CL (1) CL2023000840A1 (en)
CO (1) CO2023004345A2 (en)
MX (1) MX2023003428A (en)
PE (1) PE20231183A1 (en)
WO (1) WO2022064254A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737497B2 (en) * 1993-06-24 2017-08-22 Trutek Corp. Electrostatically charged nasal application method and product for micro-filtration
JP2012526857A (en) * 2009-05-16 2012-11-01 トルテック コーポレーション Electrostatically charged multi-action nasal application, product and method
FR2956029B1 (en) * 2010-02-09 2012-06-01 Fabre Pierre Dermo Cosmetique COSMETIC COMPOSITION, IN PARTICULAR SHAMPOO FOR CREPUS AND / OR VERY DRY HAIR

Also Published As

Publication number Publication date
MX2023003428A (en) 2023-05-10
BR112023005563A2 (en) 2023-05-09
WO2022064254A1 (en) 2022-03-31
CL2023000840A1 (en) 2023-11-24
CO2023004345A2 (en) 2023-05-08

Similar Documents

Publication Publication Date Title
NI201900013A (en) PYRIDOPYRIMIDINONE INHIBITOR CDK2 / 4/6
MX2018016393A (en) Conjugates for targeted cell surface editing.
EP2513343A4 (en) Methods and compositions for treating inflammation of skin
CO2022010432A2 (en) Method based on leaper technology for the treatment of mucopolysaccharidoses ih and composition
DOP2009000248A (en) DERIVATIVES OF SULFONIL AMIDA FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
BRPI0517238A (en) formulations comprising ecteinascidin and a disaccharide
HN2005000212A (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
AR053412A1 (en) INHIBITING COMPOUNDS OF INTERACTION BETWEEN MDM2 AND P53, A METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND TO MANUFACTURE MEDICATIONS
WO2010017264A3 (en) Photo-crosslinked nucleic acid hydrogels
BRPI0510719A (en) naphthalimide derivatives, pharmaceutical composition, use and method of preparation thereof
MX2009012978A (en) Method for silk fibroin gelation using sonication.
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
CO2021006114A2 (en) 2,3-dihydro-1h-pyrrolo [3,4-c] pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
AR081818A1 (en) BLOCK FOR CONTAINING WALL AND PROCEDURE FOR THE CONSTRUCTION OF CONTAINING WALL
BR112021023345A2 (en) Targeted immunotolerance in madcam
CO2022014527A2 (en) Method and drug to treat hurler syndrome
IL190774A0 (en) Pharmaceutical compositions containing a jorumycin-renieramycin-or saframycin-related compounds for treating proliferative diseases
CO2021001277A2 (en) Triazole glycolate oxidase inhibitors
MX2021011608A (en) Ex vivo methods for producing a t cell therapeutic and related compositions and methods.
PE20231183A1 (en) PHARMACEUTICAL COMPOSITION WITH ELECTROSTATIC CHARGE AND METHOD OF OBTAINING
WO2012090194A3 (en) Compositions and methods for treating a skin disorder
BR112023002464A2 (en) METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
CO2023011154A2 (en) Compositions and methods for treating hereditary angioedema
MX2021006808A (en) Dephosphorylation enzyme of new psicose-6-phosphoric acid, composition for producing psicose comprising same, and method for preparing psicose using same.